ClinicalTrials.gg
CompletedNCT07704697Updated Jul 15, 2026

Assess Sacubitril/Allisartan and Amlodipine in Patients With Essential Hypertension Uncontrolled With Sacubitril/Allisartan

A Phase 3 interventional study of Experimental: Sacubitril/Allisartan and Amlodipine Group and Active Comparator: Sacubitril/Allisartan Group in Essential Hypertension, sponsored by Shenzhen Salubris Pharmaceuticals Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-07-15.

Sponsored by Shenzhen Salubris Pharmaceuticals Co., Ltd. · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year 7 months after the study started (first participant enrolled Nov 2024, registered Jul 2026).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
346
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 10 studies testing losartan in Essential Hypertension — none open to participants now, none under way, none of them phase 3. Losartan · Essential Hypertension.

Enrollment
4th of 10
346 · median 284
Started
2024
the only one that year
Phase 3
5 of 10
none open now
Registered
9th of 10
by date
Lead sponsor
2 of 10
Shenzhen Salubris Pharmaceuticals Co., Ltd.

Among the 10 studies testing losartan in Essential Hypertension, this one is the 4th largest by enrollment, is the only one that started in 2024, is one of 5 in phase 3, and was the 9th registered.

Essential Hypertension

480 studies on the registry are indexed under Essential Hypertension; 75 are open to participants now.

Browse Essential Hypertension studies →

Open to participants now

None of the 10 studies testing losartan in Essential Hypertension is open now. The open studies under Essential Hypertension, anywhere →

About losartan

Losartan: first FDA approval 1995 (COZAAR). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 44 Essential Hypertension studies recruiting now, 16 (36%) set no upper age limit and 20 (45%) stop at 75 or younger; 4 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 10 studies testing losartan in Essential Hypertension as a file.
02

Study summary

The main objective of the study will be to assess the efficacy and safety of Sacubitril/Allisartan (240mg) and Amlodipine (5mg) in patients with essential hypertension uncontrolled after 4-week treatment with Sacubitril/Allisartan (240mg).

03

Conditions studied

  • Essential Hypertension

Keywords

  • Hypertension
  • Sacubitril
  • Allisartan
  • Amlodipine
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients 18-75 years old.
  2. Confirmed diagnosis of essential hypertension.
  3. Patients who meet one of the following criteria when screening:

    A. Treatment-naive patients (newly diagnosed essential hypertension, or patients with a prior hypertension history who have not taken any antihypertensive medication for at least 4 weeks prior to screening): mean seated systolic blood pressure (msSBP) ≥150 mmHg and \<180 mmHg.

    B. Patients with irregular oral administration of Sacubitril/Allisartan (240 mg once daily) (treatment duration less than 4 weeks before screening, or more than 5 missed dosing days within the 4 weeks prior to screening): msSBP ≥140 mmHg and\<180 mmHg.

    C. Patients on existing stable antihypertensive therapy (receiving a stable dose of another single-agent antihypertensive, free combination of two single-agent drugs, or single-pill fixed-dose combination containing two active ingredients for at least 4 weeks prior to screening): msSBP ≥140 mmHg and \<180 mmHg, and the physician determines that switching treatment to Sacubitril/Allisartan (240 mg once daily) is clinically appropriate.

    D. Patients with essential hypertension who have been regularly treated with Sacubitril/Allisartan (240 mg once daily) for ≥4 weeks and have msSBP ≥140 mmHg and\<180 mmHg.

  4. At randomization, subjects must have msSBP ≥140 mmHg and \<180 mmHg.
  5. Subjects voluntarily participate in the trial and sign the written form.
  6. For subjects enrolled for ambulatory blood pressure monitoring (ABPM): in addition to all above inclusion criteria, one further requirement must be satisfied: valid ABPM report with a 24-hour average blood pressure ≥130/80 mmHg. (Subjects failing to meet Criterion 6 remain eligible for the main trial without ABPM testing.)

Exclusion criteria

Exclusion Criteria:

  1. Severe hypertension (msSBP ≥180 mmHg and/or msDBP ≥110 mmHg).
  2. History or confirmed diagnosis of secondary hypertension.
  3. Concomitant use of three or more types of antihypertensive agents.
  4. Personal history of angioedema induced by drugs or other causes.
  5. abnormal laboratory findings, including but not limited to: serum potassium >5.5 mmol/L or \<3.5 mmol/L; serum and/or AST >2.5 × (ULN); serum creatinine >1.5 × ULN; any other clinically significant laboratory abnormality deemed by the investigator likely to confound efficacy and/or safety assessment of the study.
  6. Type 1 diabetes mellitus or poorly controlled type 2 diabetes mellitus .
  7. Subjects with active malignant tumor.
  8. History of substance abuse or excessive alcohol consumption within 6 months prior to screening.
  9. Blood donation or major blood loss (>400 mL) within 3 months prior to screening, or clinically diagnosed hypovolemia.
  10. Participation in any interventional clinical trial with medicinal product or medical device within 3 months prior to screening.
  11. Drug compliance during run-in period \<80% or >120%.
  12. Any other conditions deemed inappropriate for trial enrollment by the investigator that may interfere with efficacy and/or safety evaluation of the study, including but not limited to anticipated poor subject compliance or impractical regular follow-up due to long residential distance.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
346 participants (actual)

Study arms

  • Experimental
    Test Group

    Drug: Experimental: Sacubitril/Allisartan and Amlodipine Group

  • Active comparator
    Reference Group

    Drug: Active Comparator: Sacubitril/Allisartan Group

Interventions

  • DrugExperimental: Sacubitril/Allisartan and Amlodipine Group

    Drug pages: Sacubitril · Losartan · Amlodipine

    Drug: Sacubitril/Allisartan and Amlodipine

  • DrugActive Comparator: Sacubitril/Allisartan Group

    Drug pages: Sacubitril · Losartan

    Drug: Sacubitril/Allisartan

06

What researchers measure

Primary outcomes

  1. The baseline change in mean seated systolic blood pressure (msSBP)

    Change from baseline in mean seated systolic blood pressure (msSBP) after 12 weeks of randomized, double-blind treatment

    Time frame: at 12 weeks

07

Study locations

1 site
  • Peking University First Hospital
    Beijing, Beijing Municipality 100034, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2024 to primary completion in Nov 2025, 11 months.

Of 45 industry-sponsored phase 3 interventional studies under Essential Hypertension, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 24. This study's 11 months is below that.

Counting every sponsor, half of 47 studies reached it within 17 months; a quarter within 11 and three quarters within 24.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 9, 2026
First posted
Jul 15, 2026
StartActual
Nov 23, 2024
Primary completionActual
Nov 10, 2025
CompletionActual
Nov 24, 2025
Last update
Jul 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07704697
Responsible party
Sponsor
First posted
Jul 15, 2026
Start date
Nov 23, 2024
Primary completion
Nov 10, 2025
Completion
Nov 24, 2025
Last update
Jul 15, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Sacubitril · Losartan · Amlodipine

Start the discussion